GNI Group

2160.TSE

18.61 USD

0.64

+3.56%

Overview

Last close

18.61 usd

Market cap

1.03B usd

52 week high

30.23 usd

52 week low

10.22 usd

Target price

29.2 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

6.1472

Price/Book Value

4.2057

Enterprise Value

920.70M usd

EV/Revenue

5.6192

EV/EBITDA

330.4676

Key financials

Revenue TTM

163.85M usd

Gross Profit TTM

117.49M usd

EBITDA TTM

-1.88M usd

Earnings per Share

-0.03 usd

Dividend

N/A usd

Total assets

456.11M usd

Net debt

-22.20M usd

About

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.